An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Savara to Present at Two Upcoming Healthcare Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Savara Inc. (SVRA) will be participating in the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024, and the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company will be holding a fireside chat and a corporate presentation, respectively. Both presentations will be available via webcast on the company's website.
Positive
None.
Negative
None.
Guggenheim 6th Annual Biotechnology Conference
Oppenheimer 34th Annual Healthcare Life Sciences Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences:
Guggenheim 6th Annual Biotechnology Conference
February 7, 2024 at 8:30am PT/ 11:30am ET
Fireside Chat
St. Regis Hotel, New York City, NY
Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 13, 2024 at 7:40am PT / 10:40am ET
Corporate Presentation
Virtual Conference
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
When is Savara Inc. participating in the Guggenheim 6th Annual Biotechnology Conference?
Savara Inc. (SVRA) will be participating in the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024.
What type of presentation will Savara Inc. have at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?
Savara Inc. will have a corporate presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Where can I watch the webcast of Savara Inc.'s presentations?
The webcast of each presentation will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/.
How long will the webcast of Savara Inc.'s presentations be available?
The webcast will be archived for at least 30 days on the company's website.
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com